RT Journal Article
SR Electronic
T1 The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
JF Diabetes
JO Diabetes
FD American Diabetes Association
SP 797
OP 802
DO 10.2337/diabetes.51.3.797
VO 51
IS 3
A1 Mayerson, Adam B.
A1 Hundal, Ripudaman S.
A1 Dufour, Sylvie
A1 Lebon, Vincent
A1 Befroy, Douglas
A1 Cline, Gary W.
A1 Enocksson, Staffan
A1 Inzucchi, Silvio E.
A1 Shulman, Gerald I.
A1 Petersen, Kitt F.
YR 2002
UL http://diabetes.diabetesjournals.org/content/51/3/797.abstract
AB We examined the effect of three months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo peripheral adipocyte insulin sensitivity as assessed by glycerol release in microdialysis from subcutaneous fat during a two-step (20 and 120 mU · m−2 · min−1) hyperinsulinemic-euglycemic clamp in nine type 2 diabetic subjects. In addition, the effects of rosiglitazone on liver and muscle triglyceride content were assessed by 1H-nuclear magnetic resonance spectroscopy. Rosiglitazone treatment resulted in a 68% (P < 0.002) and a 20% (P < 0.016) improvement in insulin-stimulated glucose metabolism during the low- and high- dosage−insulin clamps, respectively, which was associated with ∼40% reductions in plasma fatty acid concentration (P < 0.05) and hepatic triglyceride content (P < 0.05). These changes were associated with a 39% increase in extramyocellular lipid content (P < 0.05) and a 52% increase in the sensitivity of peripheral adipocytes to the inhibitory effects of insulin on lipolysis (P = 0.04). In conclusion, these results support the hypothesis that thiazolidinediones enhance insulin sensitivity in patients with type 2 diabetes by promoting increased insulin sensitivity in peripheral adipocytes, which results in lower plasma fatty acid concentrations and a redistribution of intracellular lipid from insulin responsive organs into peripheral adipocytes.